Meta-analysis of statins in chronic kidney disease: who benefits? [PDF]
, 2017 Background: Attempts to reduce the burden of vascular disease in advanced chronic kidney disease (CKD) by control of lipids have not been as successful as predicted.
Isles, C., Messow, C.M.
core +1 more source
Ezetimibe use and mortality after myocardial infarction: A nationwide cohort study
American Journal of Preventive CardiologyBackground: The inhibition of intestinal cholesterol absorption by ezetimibe improves outcomes after myocardial infarction (MI), yet real-world data on ezetimibe is scarce. We studied the usage of ezetimibe and association with outcome after MI. Methods:
Ville Kytö, Aleksi Tornio
doaj +1 more source
Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomized controlled trials [PDF]
, 2016 Objective Previous studies have suggested that niacin treatment raises glucose levels in patients with diabetes and may increase the risk of developing diabetes.
Goldie, Christina +5 more
core +1 more source
Ezetimibe Anticancer Activity via the p53/Mdm2 Pathway
BiomedicinesBackground: Ezetimibe is used to treat cardiovascular disease as it blocks the sterol transporter Niemann-Pick C1-Like 1 (NPC1CL1) protein. However, recent evidence indicates that Ezetimibe inhibits several cancers indirectly by reducing circulating ...
Charmy Twala +4 more
doaj +1 more source
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV [PDF]
, 2007 To determine the efficacy and safety of adding ezetimibe to maximally tolerated lipid lowering therapy in patients with HIV dyslipidemia. Retrospective analysis of lipid parameters was conducted for 33 patients with HIV who had been prescribed ezetimibe ...
Matthew T Bennett +2 more
core +1 more source
Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK [PDF]
, 2017 Peer reviewedPublisher ...
Cather, Moyra +6 more
core +2 more sources
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatins⃞
Journal of Lipid Research, 2007 The combination of ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein (NPC1L1), and an HMG-CoA reductase inhibitor decreases cholesterol absorption and synthesis.
Dawn E. Telford +5 more
doaj +1 more source
Advanced Science, EarlyView.Phospholipid transfer protein(PLTP) plays a critical role in forming a complex with kinase A (AURKA) and P65. This interaction facilitates phosphorylation of P65 at Ser536, leading to the activation of the NF‐κB signaling pathway. Ultimately, this leads to the upregulation of downstream cytokines, including IL‐6, IL‐8, and CSF‐1, which promotes M2 ...
Xinyue Liang +14 more
wiley +1 more source
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9[S]
Journal of Lipid Research, 2011 Reducing circulating LDL-cholesterol (LDL-c) reduces the risk of cardiovascular disease in people with hypercholesterolemia. Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks ...
Brandon Ason +18 more
doaj +1 more source
Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. [PDF]
PLoS ONE, 2015 Ezetimibe, as a cholesterol absorption inhibitor, has been shown protecting against atherosclerosis when combined with statin. However, side by side comparison has not been made to evaluate the beneficial effects of ezetimibe alone versus statin. Herein,
Chunmiao Tie +6 more
doaj +1 more source